Dr. Reddy’s share pros and cons: India’s 2nd-largest pharma company analysed for 2026. Complex generics strategy, biosimilar pipeline, US FDA risks, and Russia market covered.

Sun Pharma share pros and cons: India’s largest pharma company analysed for 2026. Covers Ilumya specialty growth, US FDA risks, India chronic care dominance, and generic price erosion.

Meenakshi India share price in focus as Alchemy Long Term Ventures Fund Series 3 acquires 1.15 lakh shares (1.02 percent stake) for Rs 4.56 crore at Rs 396.65 on 6 August 2026.

Small cap stocks today scale a fresh market peak on 6 August 2026 driven by strong Q1 FY27 earnings and sustained SIP flows. Analysts warn valuations leave little room for disappointment.

Power Grid share pros and cons: India’s transmission monopoly analysed for 2026. Regulated income, 3.2 percent dividend yield, renewable integration opportunity, and PSU risks covered.

Dollar index today on 6 August 2026 near a six-week low at 99.65. Yen at 157.71, euro at 1.1557, sterling at 1.3469. US payroll data and Iran deal concerns keep currency markets cautious.

FII DII data for 5 August 2026: FIIs turned net sellers at Rs 943.42 crore while DIIs remained strong net buyers at Rs 2,883.17 crore. What the FII DII data means for markets.

Biogen Pharmachem Q1 results FY27: revenue Rs 0.44 Cr (-71.26% YoY), PAT Rs 22 Lakh. Financial highlights, analysis and FY27 outlook for the June 2026 quarter.

Kkalpana Plastics Q1 results FY27: revenue Rs 0 Cr (NA YoY), net loss Rs 8 Lakh. Financial highlights, analysis and FY27 outlook for the June 2026 quarter.

Siemens India share pros and cons: capital goods leader and automation technology company analysed for 2026. Covers 91x PE risk, Siemens AG technology access, and India capex cycle exposure.